Found 6 matching trials
A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors PHASE1 The purpose of this study is to evaluate the safety, tolerance, Dose-Limiti...
Show More Location
Jilin Cancer Hospital
Learn More & Join Trial
A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer PHASE2 The aim of this study is to evaluate the efficacy, safety, tolerability, ph...
Show More Location
Beijing Chest Hospital, Capital Medical University
Learn More & Join Trial
INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC PHASE2 This seamless phase 2/3 randomized controlled study will evaluate the effic...
Show More Status
Active Not Recruiting
Location
City of Hope Medical Center
Learn More & Join Trial
A Study of ES102 (OX40 Agonist) in Patients With Advanced Solid Tumors PHASE1 The purpose of this study is to evaluate the safety, tolerance, Dose-Limiti...
Show More Location
Jilin Cancer Hospital
Learn More & Join Trial
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) PHASE1 This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine ...
Show More Learn More & Join Trial
Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients PHASE2 This is a Phase II trial to assess efficacy and feasibility of pembrolizuma...
Show More Location
Ellison Institute of Technology (EITM)
Learn More & Join Trial